Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Seattle, Washington

This page shows live ClinicalTrials.gov search results for Seattle, Washington, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
11419
Shown on this page
12
Current sort
Recently updated
Location scope
Seattle, WA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Seattle, Washington. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 841–852 of 11,419 matching trials in Seattle, WA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Seattle

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 3 Interventional

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

NCT07525206
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Goodyear, Arizona • Springdale, Arkansas • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:19 PM EST
Active, not recruiting Phase 2 Interventional

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

NCT04316117
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:19 PM EST
Active, not recruiting Not applicable Interventional Results available

A Communication Tool to Improve Communication in the ICU

NCT05780918
View directory record Official record
Conditions
Serious Injury, Communication
Interventions
Best Case/Worst Case-ICU Communication Tool
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
7,320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Davis, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:19 PM EST
Active, not recruiting Phase 2 Interventional

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

NCT05710328
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure
Drug · Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:19 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

NCT06115499
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Nab paclitaxel, Gemcitabine, Cisplatin, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
345
States / cities
Anchorage, Alaska • Goodyear, Arizona • Phoenix, Arizona + 253 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:19 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

NCT07564401
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Interventions
DJI136
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Lexington, Kentucky • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:19 PM EST
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
215
States / cities
Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:19 PM EST
Recruiting Phase 3 Interventional

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

NCT07387367
View directory record Official record
Conditions
Adenovirus Infections
Interventions
cidofovir, Brincidofovir
Drug
Lead sponsor
SymBio Pharmaceuticals
Industry
Eligibility
2 Months and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Duarte, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:19 PM EST
Recruiting Phase 2 Interventional

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

NCT07228624
View directory record Official record
Conditions
Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, JAK Inhibitor, Melphalan, Methotrexate, Tacrolimus, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:19 PM EST
Recruiting Phase 3 Interventional

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

NCT06948214
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
LUM-201, Matched Placebo (Capsules)
Drug · Other
Lead sponsor
Lumos Pharma
Industry
Eligibility
3 Years to 11 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
31
States / cities
Birmingham, Alabama • Madera, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:19 PM EST
Active, not recruiting Phase 1 Interventional

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

NCT04637763
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Interventions
CB-010, Cyclophosphamide, Fludarabine
Genetic · Drug
Lead sponsor
Caribou Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
31
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:19 PM EST
Completed Phase 1 Interventional

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00825201
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, liquid chromatography, mass spectrometry, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:19 PM EST